Hematologic

« Previous 12345 Next »
Viewing Page 1 of 7 | Showing Results 1 - 10 of 63

A Phase 1/2 Multicenter Study Evaluating the Safety and Efficacy of KTE-C19 in Adult Subjects with Relapsed/Refractory Chronic Lymphocytic Leukemia

Key Inclusion Criteria:Documentation of relapsed or refractory CLL AND a minimum of two prior treatment regimens with progression on treatment with...

John Pagel, M.D.
  • Swedish Medical Center

A Phase III Trial to Evaluate the Efficacy of the Addition of Inotuzumab Ozogamicin (a Conjugated Anti-CD22 Monoclonal Antibody) to Frontline Therapy in Young Adults (Ages 18-39 Years) with Newly Diagnosed Precursor B-Cell ALL

This partially randomized phase III trial studies the side effects of inotuzumab ozogamicin and how well it works when given with frontline...

Alison Conlin, M.D.

The Pacific Cancer Research Consortium clinical trials are offered at multiple locations throughout Oregon, Washington, Alaska, California, and Idaho. To find a location near you, please contact the Patient Engagement Center at 844-552-2734.

A Phase 2b Randomized Study to Assess the Efficacy and Safety of the Combination of Ublituximab + TGR-1202 and TGR-1202 Alone in Patients With Previously Treated Diffuse Large B-Cell Lymphoma

A Phase 2b Randomized Study to Assess the Efficacy and Safety of the Combination of Ublituximab + TGR-1202 and TGR-1202 Alone in Patients With...

John Pagel, M.D.
  • Swedish Medical Center

Phase 1/2 Open Label, Multi-center, Dose-Escalation Study to Assess the Safety, Tolerability and Pharmacokinetics of Orally Administered Fimepinostat (CUDC-907), a PI3K and HDAC Inhibitor, in Subjects With Refractory or Relapsed Lymphoma

Inclusion Criteria:Subjects of ≥ 18 years of age with any of the following:For Dose-Escalation cohorts:Fimepinostat + venetoclax:...

Krish Patel, M.D.
  • Swedish Medical Center

Connect® MDS/AML: The Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Disease Registry

The purpose of the Connect® MDS/AML Disease Registry is to provide unique insights into treatment regimens and sequencing of these regimens as they...

James Congdon, DO
  • Providence Regional Cancer Partnership - Everett

A Randomized (1:1), Double-blind, Multi-center, Placebo Controlled Study Evaluating Intensive Chemotherapy With Or Without Glasdegib (Pf-04449913) Or Azacitidine (Aza) With Or Without Glasdegib In Patients With Previously Untreated Acute Myeloid Leukemia

A Study Evaluating Intensive Chemotherapy With or Without Glasdegib or Azacitidine With or Without Glasdegib In Patients With Previously Untreated...

Raya Mawad, M.D.
  • Swedish Medical Center
« Previous 12345 Next »
Viewing Page 1 of 7 | Showing Results 1 - 10 of 63